Leila E Mansoor

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6035884/publications.pdf

Version: 2024-02-01

21 papers	3,441 citations	840585 11 h-index	752573 20 g-index
22 all docs	22 docs citations	22 times ranked	3435 citing authors

#	Article	IF	Citations
1	Effectiveness and Safety of Tenofovir Gel, an Antiretroviral Microbicide, for the Prevention of HIV Infection in Women. Science, 2010, 329, 1168-1174.	6.0	2,239
2	Genital Inflammation and the Risk of HIV Acquisition in Women. Clinical Infectious Diseases, 2015, 61, 260-269.	2.9	354
3	Vaginal bacteria modify HIV tenofovir microbicide efficacy in African women. Science, 2017, 356, 938-945.	6.0	348
4	Genital inflammation undermines the effectiveness of tenofovir gel in preventing HIV acquisition in women. Nature Medicine, 2018, 24, 491-496.	15.2	123
5	Tenofovir Gel for the Prevention of Herpes Simplex Virus Type 2 Infection. New England Journal of Medicine, 2015, 373, 530-539.	13.9	80
6	Cervicovaginal Inflammation Facilitates Acquisition of Less Infectious HIV Variants. Clinical Infectious Diseases, 2017, 64, 79-82.	2.9	53
7	Disclosure of Microbicide Gel Use to Sexual Partners: Influence on Adherence in the CAPRISA 004 Trial. AIDS and Behavior, 2014, 18, 849-854.	1.4	44
8	Adherence challenges with drugs for pre-exposure prophylaxis to prevent HIV infection. International Journal of Clinical Pharmacy, 2014, 36, 70-85.	1.0	43
9	HPV infection and the genital cytokine milieu in women at high risk of HIV acquisition. Nature Communications, 2019, 10, 5227.	5.8	40
10	Recruitment of high risk women for HIV prevention trials: baseline HIV prevalence and sexual behavior in the CAPRISA 004 tenofovir gel trial. Trials, 2011, 12, 67.	0.7	33
11	Safety of Tenofovir Gel, a Vaginal Microbicide, in South African Women: Results of the Caprisa 004 Trial. Antiviral Therapy, 2013, 18, 301-310.	0.6	21
12	Integrated provision of topical preâ€exposure prophylaxis in routine family planning services in South Africa: a nonâ€inferiority randomized controlled trial. Journal of the International AIDS Society, 2019, 22, e25381.	1.2	13
13	Social Context of Adherence in an Open-Label 1Â% Tenofovir Gel Trial: Gender Dynamics and Disclosure in KwaZulu-Natal, South Africa. AIDS and Behavior, 2016, 20, 2682-2691.	1.4	12
14	Undue inducement: a case study in CAPRISA 008. Journal of Medical Ethics, 2017, 43, 824-828.	1.0	10
15	Assessing the implementation effectiveness and safety of 1% tenofovir gel provision through family planning services in KwaZulu-Natal, South Africa: study protocol for an open-label randomized controlled trial. Trials, 2014, 15, 496.	0.7	9
16	Transient association between semen exposure and biomarkers of genital inflammation in South African women at risk of HIV infection. Journal of the International AIDS Society, 2021, 24, e25766.	1.2	5
17	The Impact of Semen Exposure on the Immune and Microbial Environments of the Female Genital Tract. Frontiers in Reproductive Health, 2020, 2, .	0.6	4
18	Importance of early identification of PrEP breakthrough infections in a generalized HIV epidemic: a case report from a PrEP demonstration project in South Africa. BMC Infectious Diseases, 2020, 20, 532.	1.3	3

#	Article	IF	Citations
19	Higher mucosal antibody concentrations in women with genital tract inflammation. Scientific Reports, 2021, 11, 23514.	1.6	3
20	Genital immune cell activation and tenofovir gel efficacy: a case-control study. Clinical Infectious Diseases, 2022, , .	2.9	2
21	Measurement of Vaginal Microbicide Adherence Using Visual Inspection as Compared to Ultra Violet Light Assessment of Returned Empty Gel Applicators. AIDS and Behavior, 2017, 21, 462-469.	1.4	1